Myricx Pharma

Myricx Bio is a biotechnology company developing novel cancer therapeutics, with a focus on antibody-drug conjugates (ADCs). Its work centres on a proprietary N-myristoyltransferase inhibitor (NMTi) payload chemistry platform, designed to create selective cytotoxic payloads for next-generation oncology treatments. The company is building a pipeline of ADC medicines targeting solid tumours and other cancers with significant unmet clinical needs. Its services and activities span drug discovery, preclinical development, translational research, pipeline development and strategic partnerships within the biopharmaceutical industry. Myricx Bio operates in the life sciences, oncology and advanced therapeutics sectors.